Abstract
Human Genome Sciences Inc. of Rockville, Maryland, the company in the forefront of efforts to use modern genomics to develop new drugs (see main text), has three potential therapies based on those genes wending their way through clinical testing. Some attribute the success of company CEO William Haseltine to his practical bent as much as his scientific sense. He likes to explore potential uses for scientific advances, they say--and does so aggressively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
